mglur1a

Ro 67-7476 is a positive allosteric modulator of mGlu1 receptors. No activity at human mGlu1 receptors. Potentiates glutamate-induced calcium release with EC 50 of 60.1 nM.

LY341495 is a potent metabotropic glutamate receptor antagonist that exhibits high activity against a wide range of glutamate receptor subtypes and can be used for the study of neurological disorders.

LY367385 is a highly effective and selective mGluR1a antagonist. LY367385 has neuroprotective, anticonvulsant, and antiepileptic effects. Compared with > 100 μM for mGlu5a, LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis.

group I metabotropic glutamate receptors (mGlu1a) antagonist

Ro 67-4853 is a selective mGluR1 positive allosteric modulator, enhancing the response to the agonist (S)-3,5-dihydroxyphenylglycine (DHPG) in anesthetized rats through iontophoretic administration.

group I mGlu receptor agonist

CFMTI is a potent and selective metabotropic glutamate receptor (mGluR) 1 allosteric antagonist (IC50: 2.6 nM). The selectivity of CFMTI to mGluR1 is higher 2000-fold than mGluR5.

FTIDC is a highly potent and selective allosteric antagonist of mGluR1 receptors and shows very weak potency against human and rat mGluR5 receptors. The inhibition of FTIDC for mGluR1 receptors is shown to be in noncompetitive manner and displays IC50 val

(±)-LY367385 is the racemic form of LY367385, and LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 exhibits a high inhibitory activity against quisqualate-induced phosphoinositide (PI) hydrolysis, with an IC50 value of 8.8 μM. In contrast, its inhibitory activity against mGlu5a is greater than 100 μM.

LY367385 hydrochloride is a potent and selective mGluR1a antagonist with an IC50 value of 8.8 μM for inhibiting quisqualate-induced phosphoinositide (PI) hydrolysis, showing significantly higher selectivity compared to its >100 μM IC50 value for mGlu5a. This compound exhibits neuroprotective, anticonvulsant, and antiepileptic effects [1] [2].